NeOnc Reports Additional Partial Response in Phase 2a Study of Intranasal NEO100
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NeOnc Technologies Holdings (NTHI) reported an additional partial response in its Phase 2a study of intranasal NEO100 for recurrent or progressive glioma. The interim RANO 2.0 objective response rate rose to 12.5% (3 of 24 patients) from 8.3% in the August 12, 2026 topline results. Patients had Grade III or IV IDH1-mutant glioma.
Previously reported six-month progression-free survival, the primary endpoint, was 48.9% versus a prespecified 20% historical benchmark; median overall survival was 26.1 months from treatment initiation at recurrence. Disease control was 66.7%. All reported treatment-related adverse events were Grade 1 or 2, with no treatment-related serious adverse events or discontinuations. The single-arm, open-label study had no randomized control group. Results differ under protocol-specified response criteria and estimation methods, and interim findings may change at final analysis.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointSix-month progression-free survival was 48.9% versus the prespecified 20% historical benchmark (one-sided p = 0.0047).
- Moderate pointObjective response rate reached 12.5% (3 of 24), versus 8.3% (2 of 24) in August, using RANO 2.0.
- Moderate pointMedian overall survival was 26.1 months (95% CI, 8.5–27.1 months) from NEO100 treatment initiation at recurrence.
- Minor pointStable disease occurred in 13 patients (54.2%) under RANO 2.0.
- Minor pointTreatment-related adverse events included no serious events or treatment discontinuations.
Negative
- Moderate pointSingle-arm, open-label design used a historical benchmark without a randomized control group.
- Minor pointProgressive disease occurred in eight patients (33.3%) under RANO 2.0.
- Minor pointTreatment-related adverse events were Grade 1 or 2, predominantly local nasal or upper-airway effects.
- Minor pointResults differ under the response criteria and estimation method specified in the study protocol.
- Minor point. Forward-looking: it has not happened yet and may not happen.Interim results may change at final analysis.
Key Figures
- Objective response rate
- 12.5% (3 of 24 patients), compared with 8.3% (2 of 24 patients)
- Updated interim results vs. August topline; RANO 2.0
- Six-month progression-free survival
- 48.9% (95% CI, 26.3%–68.1%); one-sided p = 0.0047
- RANO 2.0; compared with the prespecified 20% historical benchmark
- Median overall survival
- 26.1 months (95% CI, 8.5–27.1 months)
- From the start of NEO100 treatment at recurrence
- Disease control rate
- 66.7%
- Updated interim results
- Treatment-related adverse events
- All reported events were Grade 1 or 2
- Interim analysis
Previous Clinical trial Reports
-
August topline reported two objective responses among 24 patients under RANO 2.0 criteria.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
kaplan–meier estimation medical
idh1-mutant medical
open-label medical
single-arm medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Objective response rate was
Median overall survival was 26.1 months from the start of NEO100 treatment at recurrence, as previously reported
CALABASAS, Calif., Nov. 17, 2026 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (Nasdaq: NTHI) (“NeOnc” or the “Company”), a clinical-stage biopharmaceutical company developing therapies for central nervous system (CNS) cancers, today reported updated interim results from the Phase 2a portion of NEO100-01, an open-label study of intranasal NEO100 in patients with recurrent or progressive Grade III or Grade IV IDH1-mutant glioma. One additional partial response brought the objective response rate to
By RANO 2.0 criteria, three patients had a partial response (
As previously reported, six-month progression-free survival, the study’s primary endpoint, was
“We are encouraged by the additional partial response in this update,” said Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer of NeOnc. “We remain focused on advancing the development of NEO100 for patients with recurrent high-grade glioma.”
At the interim analysis, all reported treatment-related adverse events were Grade 1 or 2 and consisted predominantly of local nasal or upper-airway effects. NeOnc reported no treatment-related serious adverse events or discontinuations due to treatment-related adverse events.
About the NEO100-01 Study
NEO100-01 is an open-label, multicenter Phase 1/2a study of intranasal NEO100 in patients with radiographically confirmed progression or recurrence of primary or secondary Grade IV glioma or Grade III astrocytoma harboring an IDH1 mutation. In Phase 2a, 28 patients received the recommended Phase 2 dose of 1,152 mg/day. The efficacy population consisted of 24 patients with IDH1-mutant tumors, including 21 with Grade IV disease. Enrollment is complete.
About NEO100
NEO100 is a highly purified form of perillyl alcohol administered intranasally. Its delivery approach is designed to provide a non-invasive route to the brain. NEO100 remains investigational, and its safety and efficacy have not been established. NEO100 has received Orphan Drug designation from the FDA for the treatment of gliomas.
About NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. is a clinical-stage biopharmaceutical company developing therapies for central nervous system cancers. Its investigational programs include intranasal NEO100 and oral NEO212. NEO212 has completed Phase 1 dose escalation and is advancing toward Phase 2 development. NeOnc exclusively licenses a worldwide portfolio of issued patents and pending applications from the University of Southern California related to NEO100, NEO212 and other drug candidates and delivery approaches. For more information, visit https://neonc.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding the interpretation and significance of the updated Phase 2a results, the Company’s clinical development programs and the clinical potential of NEO100 and NEO212. These statements reflect current expectations and involve risks and uncertainties. NEO100 and NEO212 are investigational, and neither has been approved by any regulatory authority. Future studies may not demonstrate safety or efficacy. Clinical development remains subject to applicable clinical, regulatory and institutional requirements, and no regulatory pathway or marketing approval is assured.
The NEO100 Phase 2a study was a single-arm, open-label study that was not powered as a confirmatory trial. The interim results may change at final analysis. Comparisons with historical benchmarks were made without a randomized control group. The efficacy results presented reflect RANO 2.0 criteria and Kaplan–Meier estimation, and results differ under the response criteria and estimation method specified in the study protocol. The Company will require substantial additional capital to fund its operations, which may not be available on acceptable terms or at all. Actual results may differ materially. Readers should consider the risk factors described in the Company’s most recent filings with the Securities and Exchange Commission. These statements speak only as of the date of this release. The Company undertakes no obligation to update forward-looking statements except as required by law.
“NEO100” and “NEO212” are registered trademarks of NeOnc Technologies Holdings, Inc.
Contacts
Company Contact
info@neonc.com
Investor Contact
Jon Nugent
Jon Nugent Communications
jon@jonnugent.com
205-566-3026
This press release was published by a CLEAR® Verified individual.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did NeOnc's NEO100 Phase 2a update show about tumor responses?
The RANO 2.0 objective response rate reached 12.5% (3 of 24 patients), compared with 8.3% (2 of 24 patients) in the August 12, 2026 topline results. One additional partial response accounted for the increase. The disease control rate was 66.7%.
What was the primary endpoint result in NeOnc's NEO100 Phase 2a study?
Six-month progression-free survival was 48.9% (95% CI, 26.3%–68.1%), compared with the prespecified 20% historical benchmark (one-sided p = 0.0047). This previously reported primary endpoint result used RANO 2.0 criteria and Kaplan–Meier estimation, a method for estimating outcomes over time.
How many patients remained on NEO100 treatment at NeOnc's interim database lock?
Five patients remained on treatment at the interim database lock.